A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema

Secondary Lymphedema Clinical Trial

Official title:

A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Lymfactin® (AdAptVEGF-C Adenoviral Vector) in Combination With a Surgical Lymph Node Transfer for the Treatment of Patients With Secondary Lymphedema

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02994771
• Other study ID #: CL12001
• Status: Terminated
• Phase: Phase 1
• Start date: June 2016
• Est. completion date: April 5, 2022

Study information

• Verified date: April 2023
• Source: Herantis Pharma Plc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Indicated for the Treatment of Secondary Lymphedema Associated with the Treatment of Breast Cancer. Primary objective is to evaluate the safety and tolerability of a single dose of Lymfactin® in patients with secondary lymphedema associated with the treatment of breast cancer.

Description:

This is an open label, multi-center, uncontrolled first in human trial that uses a standard 3 + 3 dose escalation scheme. Lymfactin® will be administered as a single dose by ex vivo perinodal injection into the fat pad of a flap of tissue containing lymph nodes from the abdominal wall. This flap of tissue will then be surgically implanted into the axillary region of the affected arm. This treatment with Lymfactin® may be performed in conjunction with or without breast reconstruction surgery. Up to two dose cohorts are planned to be included. Each dose of Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL: - Cohort 1: Lymfactin® [1 x 10E10 vp] - Cohort 2: Lymfactin® [1 x 10E11 vp] Should the dose escalation go up to Cohort 2 with initiation of a subsequent Extension Cohort a total of 15 - 21 patients may be treated in this study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 15
• Est. completion date: April 5, 2022
• Est. primary completion date: February 3, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion criteria:

1. Female patients with secondary lymphedema associated with the treatment of breast cancer.

2. Patient who understands and voluntarily signs informed consent prior to any screening procedure.

3. 18 - 70 years of age.

4. BMI between 18 and 32 inclusive.

5. Female patients with secondary lymphedema in the arm associated with breast cancer

who:

1. Have undergone sentinel lymph node biopsies and/or lymph node resection in the axilla on the affected side of their breast cancer with initial N1 staging and lymph node metastasis in = three lymph nodes.

2. Require garment use as a compression treatment for the lymphedema in the affected arm.

3. Have the volume of the affected arm at least 10% greater than the unaffected arm following 7 days after removal of the compression garments.

4. Have the presence of pitting edema in the affected arm without compression garments.

6. No evidence of recurrent or active breast cancer at least 2 years and no more than 5 years after breast cancer surgery and/or the end of chemotherapy and/or radiotherapy (excluding endocrine and/or aromatase inhibitor treatment). PET CT scan of the chest and the abdomen within 45 days of treatment with Lymfactin® without signs of active breast cancer or any other malignancy.

7. Patient with the following laboratory values:

1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 times the institutional upper limit of normal (ULN)

2. Bilirubin = 1.5 mg/dL

3. PT and PTT = 1.5 times the ULN

4. Serum creatinine = 2 mg/dL

5. Absolute neutrophil count (ANC) = 1,500 cells/mm³

6. Platelet count = 100,000/mm³

7. Hemoglobin = 10 g/dL

8. Willingness to comply with scheduled visits, laboratory assessments, and other study-related procedures due to the regulatory requirements related to gene based therapies.

9. Non-smoker or willing to stop smoking or using nicotine-containing products for at least 4 weeks prior to entry to study.

10. Negative urine pregnancy test (only patients with childbearing potential) at screening and use of adequate contraceptive measures from screening until 6 months after the

study treatment administration:

1. A patient with childbearing potential should be using a reliable contraception method: intrauterine device (hormonal or non-hormonal); oral combination pill or hormonal contraception patch; or two of the following: intra-vaginal hormonal ring, oral contraceptive containing progestin only, spermicidal foam, condom, sterilization of male sexual partner (surgical vasectomy).

2. A patient with no current heterosexual relationship may be included according to the judgement of the Investigator.

3. If the patient is surgically sterile or whose menopause occurred 2 years previously at the minimum, no contraception is required nor pregnancy test.

Exclusion criteria:

1. A patient who had an N2/N3 or a T4 stage breast cancer or an inflammatory breast cancer at the time of the original diagnosis.

2. A patient with evidence (clinical, laboratory, or imaging) or history of a neoplasm other than breast cancer (except basal cell carcinoma or cervical in situ carcinoma).

3. A patient known to be pregnant, lactating or having a positive or indeterminate pregnancy test.

4. Treatment with COX-2 inhibitors should be interrupted from one week prior until 2 weeks post surgery and treatment with Lymfactin®.

5. Previous treatment with, or participation in, trial of a gene therapy product.

6. Current participation or participation in the preceding two months, in any clinical study apart from a noninterventional study.

7. Current treatment with immunosuppressive drugs.

8. Current or history of drug, including nicotinecontaining products, or alcohol abuse.

9. Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related illness.

10. Allergy to any ingredients of the Lymfactin® solution for injection (glycerol, N-2-hydroxyethylpiperazine-N´-2-ethanesulfonic acid (HEPES), sodium hydroxide).

11. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, that would affect the patient's ability to follow study-related procedures, or that may interfere with the interpretation of study results and, in the Investigator's opinion, would make the patient inappropriate for entry into this study.

12. Doubtful availability, in the opinion of the Investigator, to complete the study.

Related Conditions & MeSH terms

• Lymphedema
• Neoplasm Metastasis
• Secondary Lymphedema

Intervention

Drug:
• Lymfactin® [1 x 10E10 vp]
Lymfactin® [1 x 10E10 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
• Lymfactin® [1 x 10E11 vp]
Lymfactin® [1 x 10E11 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.

Locations

Country	Name	City	State
Finland	Toeoeloe Hospital, Department of Plastic Surgery	Helsinki
Finland	Tampere University Hospital, Department of Plastic Surgery	Tampere
Finland	Turku University Hospital, Department of Plastic Surgery	Turku

Sponsors (1)

Lead Sponsor	Collaborator
Herantis Pharma Plc.

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety as measured by number of patients with treatment related adverse events and serious adverse events as assessed by CTCAE v4.0	Adverse events and serious adverse events assessed by CTCAE v4.0 to evaluate the safety profile after administration of Lymfactin	baseline to 1 year, yearly up to 5 years
Primary	CT scan of chest and abdomen	Changes in the CT scan of chest and abdomen in order to detect malignancies	baseline, yearly up to 5 years
Primary	Biodistribution of Lymfactin in blood	Changes in Lymfactin genome copy number in blood	90 days
Primary	Formation of anti-Lymfactin antibodies	Changes in the anti-Lymfactin antibody titer in blood	6 months
Secondary	Measurement of the volume of the arms	Changes in the volume of the affected arm and comparison to the unaffected arm	baseline, 6, 12, 24 and 36 months
Secondary	Measurement of the lymphatic flow of the affected arm by quantitative lymphoscintigraphy (99Tc-nanocolloid clearance rate with calculation of transport index)	Assessment of the changes in the lymphatic flow	baseline, 12, 24 and 36 months
Secondary	Questionnaire according to the Lymphedema Quality of Life Inventory (LQOLI)	Assessment of changes in the quality of life using Lymphedema Quality of Life Inventory (LQOLI) in which patients assess how their lymphedema is affecting the activities of daily living. LQOLI consists of three dimensions: Physical, psychosocial and practical, which are reported separately as the mean score of each dimension. Each dimension of the LQOLI is scored from 0 to 3, where score 0 means "no impact", 1 means "a little bit impact", 2 means "somewhat impact", and 3 means "significant impact" on the quality of life of the patient, the smaller score thus being the better.	baseline, 6, 12, 24 and 36 months